ATE533514T1 - Verzweigtes polyethylen-glykol zur verknüpfung von polymerresten mit antikörpern - Google Patents
Verzweigtes polyethylen-glykol zur verknüpfung von polymerresten mit antikörpernInfo
- Publication number
- ATE533514T1 ATE533514T1 AT04806061T AT04806061T ATE533514T1 AT E533514 T1 ATE533514 T1 AT E533514T1 AT 04806061 T AT04806061 T AT 04806061T AT 04806061 T AT04806061 T AT 04806061T AT E533514 T1 ATE533514 T1 AT E533514T1
- Authority
- AT
- Austria
- Prior art keywords
- polyethylene glycol
- antibodies
- branched polyethylene
- polymer residue
- linking polymer
- Prior art date
Links
- 239000002202 Polyethylene glycol Substances 0.000 title abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 title abstract 2
- 229920000642 polymer Polymers 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 abstract 1
- 239000002062 molecular scaffold Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Polyethers (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Jellies, Jams, And Syrups (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0329825.4A GB0329825D0 (en) | 2003-12-23 | 2003-12-23 | Biological products |
| PCT/GB2004/005246 WO2005061005A2 (en) | 2003-12-23 | 2004-12-14 | Branched polyethylene glycol for linking polymer residues to antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE533514T1 true ATE533514T1 (de) | 2011-12-15 |
Family
ID=30776372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04806061T ATE533514T1 (de) | 2003-12-23 | 2004-12-14 | Verzweigtes polyethylen-glykol zur verknüpfung von polymerresten mit antikörpern |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7736635B2 (de) |
| EP (1) | EP1699491B1 (de) |
| JP (1) | JP4833857B2 (de) |
| AT (1) | ATE533514T1 (de) |
| AU (1) | AU2004305291B2 (de) |
| CA (1) | CA2545805A1 (de) |
| ES (1) | ES2374201T3 (de) |
| GB (1) | GB0329825D0 (de) |
| WO (1) | WO2005061005A2 (de) |
Families Citing this family (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
| WO2006102659A2 (en) * | 2005-03-23 | 2006-09-28 | Nektar Therapeutics Al, Corporation | CONJUGATES OF AN hGH MOIETY AND A POLYMER |
| AU2006290567A1 (en) | 2005-09-14 | 2007-03-22 | Ucb Pharma S.A | Comb polymers |
| SG196697A1 (en) | 2007-03-22 | 2014-02-13 | Biogen Idec Inc | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
| JP2011519342A (ja) * | 2007-12-13 | 2011-07-07 | アドゥロ バイオテック | リガンド結合温熱療法サセプタおよびその作成方法 |
| HUE054585T2 (hu) * | 2008-04-29 | 2021-09-28 | Ascendis Pharma Endocrinology Div A/S | Pegilezett rekombináns humán növekedési hormon vegyületek |
| CH700543A2 (de) * | 2009-03-03 | 2010-09-15 | Innogel Ag | Film auf Basis von Stärke. |
| CA2783296C (en) | 2009-12-15 | 2019-01-15 | Ascendis Pharma As | Growth hormone composition |
| US8816099B2 (en) | 2010-03-31 | 2014-08-26 | Nof Corporation | Polyfunctional polyoxyalkylene compound, and producing method and intermediate thereof |
| JP5945896B2 (ja) | 2011-09-30 | 2016-07-05 | 日油株式会社 | 分岐型ヘテロ多官能性ポリオキシアルキレン化合物、及びその中間体 |
| KR102023401B1 (ko) | 2012-05-10 | 2019-11-04 | 바이오아트라, 엘엘씨 | 다중-특이적 모노클로날 항체 |
| CN103933575B (zh) * | 2013-01-23 | 2017-09-29 | 上海新理念生物医药科技有限公司 | 一种三齿型连接子及其应用 |
| CA2935423C (en) | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| AU2015210750B2 (en) | 2014-01-31 | 2020-08-20 | Children's Medical Center Corporation | Antibody molecules to TIM-3 and uses thereof |
| WO2015138920A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| EP3593812A3 (de) | 2014-03-15 | 2020-05-27 | Novartis AG | Behandlung von krebs mithilfe eines chimären antigenrezeptors |
| US9777061B2 (en) | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
| MY181834A (en) | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| US20170209492A1 (en) | 2014-07-31 | 2017-07-27 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
| WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
| SG11201700770PA (en) | 2014-08-19 | 2017-03-30 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| ES2891332T3 (es) | 2014-09-17 | 2022-01-27 | Novartis Ag | Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva |
| WO2016061142A1 (en) | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| ES2947818T3 (es) | 2014-11-18 | 2023-08-21 | Ascendis Pharma Endocrinology Div A/S | Nuevos profármacos poliméricos de la HCh |
| ES2896971T3 (es) | 2014-11-21 | 2022-02-28 | Ascendis Pharma Endocrinology Div A/S | Formas de administración de hormona del crecimiento de acción prolongada |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| EP3286211A1 (de) | 2015-04-23 | 2018-02-28 | Novartis AG | Behandlung von krebs mit chimärem antigenrezeptor- und proteinkinase-a-blocker |
| JP7573262B2 (ja) * | 2015-07-12 | 2024-10-25 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． | 細胞結合分子の共役のための架橋連結体 |
| WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| EP4378957A3 (de) | 2015-07-29 | 2024-08-07 | Novartis AG | Kombinationstherapien mit antikörpermolekülen gegen pd-1 |
| ES2878188T3 (es) | 2015-07-29 | 2021-11-18 | Novartis Ag | Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3 |
| RU2018125603A (ru) | 2015-12-17 | 2020-01-21 | Новартис Аг | Комбинация ингибитора с-мет с молекулой антитела к pd-1 и ее применения |
| EP3389712B1 (de) | 2015-12-17 | 2024-04-10 | Novartis AG | Antikörpermoleküle gegen pd-1 und verwendungen davon |
| PT3393504T (pt) | 2015-12-22 | 2025-12-30 | Novartis Ag | Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena |
| EP3405492B1 (de) | 2016-01-21 | 2020-10-21 | Novartis AG | Gegen cll-1 gerichtete multispezifische moleküle |
| CA3016287A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| EP3443096B1 (de) | 2016-04-15 | 2023-03-01 | Novartis AG | Zusammensetzungen und verfahren zur selektiven expression von chimären antigenrezeptoren |
| US20210177896A1 (en) | 2016-06-02 | 2021-06-17 | Novartis Ag | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
| SG11201900344YA (en) | 2016-07-15 | 2019-02-27 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| CN110214150A (zh) | 2016-07-28 | 2019-09-06 | 诺华股份有限公司 | 嵌合抗原受体和pd-1抑制剂的组合疗法 |
| EP3490590A2 (de) | 2016-08-01 | 2019-06-05 | Novartis AG | Behandlung von krebs unter verwendung eines chimären antigenrezeptors in kombination mit einem inhibitor eines pro-m2-makrophagenmoleküls |
| WO2018067992A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
| EP3574005B1 (de) | 2017-01-26 | 2021-12-15 | Novartis AG | Cd28-zusammensetzungen und verfahren für chimäre antigenrezeptortherapie |
| US20200048359A1 (en) | 2017-02-28 | 2020-02-13 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
| JP2020105072A (ja) * | 2017-03-24 | 2020-07-09 | 協和キリン株式会社 | ポリエチレングリコール誘導体 |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| US11312783B2 (en) | 2017-06-22 | 2022-04-26 | Novartis Ag | Antibody molecules to CD73 and uses thereof |
| US20200223924A1 (en) | 2017-06-27 | 2020-07-16 | Novartis Ag | Dosage regimens for anti-tim-3 antibodies and uses thereof |
| EP3652209A2 (de) | 2017-07-11 | 2020-05-20 | Compass Therapeutics LLC | Agonistische antikörper zur bindung von humanem cd137 und verwendungen davon |
| KR20200031659A (ko) | 2017-07-20 | 2020-03-24 | 노파르티스 아게 | 항-lag-3 항체의 투여 요법 및 그의 용도 |
| WO2019089798A1 (en) | 2017-10-31 | 2019-05-09 | Novartis Ag | Anti-car compositions and methods |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| CN111655288A (zh) | 2017-11-16 | 2020-09-11 | 诺华股份有限公司 | 组合疗法 |
| EP3713961A2 (de) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137-antikörper und tumorantigenbindende antikörper sowie deren verwendung |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| AU2019215031C1 (en) | 2018-01-31 | 2026-02-26 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| EP3784351A1 (de) | 2018-04-27 | 2021-03-03 | Novartis AG | Car-t-zelltherapien mit erhöhter wirksamkeit |
| WO2019226658A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Multispecific antigen-binding compositions and methods of use |
| WO2019226617A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by nk cells |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| AU2019284911B2 (en) | 2018-06-13 | 2026-04-09 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
| CN112513081A (zh) | 2018-06-14 | 2021-03-16 | 生物蛋白有限公司 | 多重特异性抗体构建体 |
| KR20210035173A (ko) | 2018-06-19 | 2021-03-31 | 아타르가, 엘엘씨 | 보체 성분 5에 대한 항체분자 및 이의 용도 |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| JP2021531306A (ja) | 2018-07-25 | 2021-11-18 | アドバンスド アクセラレーター アプリケーションズ エスエー | 神経内分泌腫瘍の処置の方法 |
| WO2020102387A1 (en) | 2018-11-13 | 2020-05-22 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
| JP2022514280A (ja) | 2018-12-20 | 2022-02-10 | ノバルティス アーゲー | Ｍｄｍ２阻害剤のための延長低用量レジメン |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| ES3032659T3 (en) | 2019-02-15 | 2025-07-23 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US10871640B2 (en) | 2019-02-15 | 2020-12-22 | Perkinelmer Cellular Technologies Germany Gmbh | Methods and systems for automated imaging of three-dimensional objects |
| BR112021015672A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| GB2597851B (en) | 2019-02-21 | 2024-05-29 | Marengo Therapeutics Inc | Antibody molecules that bind to NKP30 and uses thereof |
| US20220088075A1 (en) | 2019-02-22 | 2022-03-24 | The Trustees Of The University Of Pennsylvania | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
| EP3934625A1 (de) | 2019-03-04 | 2022-01-12 | Ascendis Pharma Endocrinology Division A/S | Langwirkende wachstumshormon-darreichungsformen mit überlegener wirksamkeit gegenüber täglichem somatropin |
| JP2022527790A (ja) | 2019-03-29 | 2022-06-06 | アターガ，エルエルシー | 抗ｆｇｆ２３抗体分子 |
| CA3158298A1 (en) | 2019-10-21 | 2021-04-29 | Novartis Ag | Combination therapies with venetoclax and tim-3 inhibitors |
| TW202128191A (zh) | 2019-10-21 | 2021-08-01 | 瑞士商諾華公司 | Tim-3抑制劑及其用途 |
| EP4065158A2 (de) | 2019-11-26 | 2022-10-05 | Novartis AG | Chimäre antigenrezeptoren bindende bcma und cd19 und verwendungen davon |
| KR20220116257A (ko) | 2019-12-20 | 2022-08-22 | 노파르티스 아게 | 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물 |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| EP4090762A1 (de) | 2020-01-17 | 2022-11-23 | Becton, Dickinson and Company | Methoden und zusammensetzungen für einzelzellsekretomik |
| US20230058489A1 (en) | 2020-01-17 | 2023-02-23 | Novartis Ag | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
| MX2022010685A (es) | 2020-02-27 | 2022-09-23 | Novartis Ag | Metodos de produccion de celulas que expresan receptores de antigeno quimericos. |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| US11524998B2 (en) | 2020-07-16 | 2022-12-13 | Novartis Ag | Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules |
| WO2022026592A2 (en) | 2020-07-28 | 2022-02-03 | Celltas Bio, Inc. | Antibody molecules to coronavirus and uses thereof |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| EP4204020A1 (de) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Verfahren zur behandlung von psma-exprimierenden krebsarten |
| JP2023547499A (ja) | 2020-11-06 | 2023-11-10 | ノバルティス アーゲー | 抗体Ｆｃ変異体 |
| MX2023005609A (es) | 2020-11-13 | 2023-05-29 | Novartis Ag | Terapias de combinacion con celulas que expresan receptores quimericos para el antigeno (car). |
| EP4284510A1 (de) | 2021-01-29 | 2023-12-06 | Novartis AG | Dosierungsschemata für anti-cd73- und anti-enpd2-antikörper und verwendungen davon |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| EP4405396A2 (de) | 2021-09-20 | 2024-07-31 | Voyager Therapeutics, Inc. | Zusammensetzungen und verfahren zur behandlung von her2-positivem krebs |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| TW202342548A (zh) | 2022-02-07 | 2023-11-01 | 美商威特拉公司 | 抗獨特型(anti-idiotype)抗體分子及其用途 |
| EP4522757A2 (de) | 2022-05-13 | 2025-03-19 | Voyager Therapeutics, Inc. | Zusammensetzungen und verfahren zur behandlung von her2-positivem krebs |
| JP2025528068A (ja) | 2022-08-03 | 2025-08-26 | ボイジャー セラピューティクス インコーポレイテッド | 血液脳関門を通過させるための組成物及び方法 |
| WO2024168061A2 (en) | 2023-02-07 | 2024-08-15 | Ayan Therapeutics Inc. | Antibody molecules binding to sars-cov-2 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2026036047A1 (en) | 2024-08-08 | 2026-02-12 | Altus Enterprises, Inc. | Antibody molecules to fixa and fx and uses thereof |
| WO2026058155A1 (en) | 2024-09-11 | 2026-03-19 | Novartis Ag | Antibodies targeting il-31 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB315450A (en) | 1928-04-10 | 1929-07-10 | Hozumi Kita | Improvements in door controlling apparatus |
| GB315457A (en) | 1928-04-13 | 1929-07-15 | Reyrolle A & Co Ltd | Improvements in or relating to electric couplings |
| US1890060A (en) | 1928-09-22 | 1932-12-06 | Du Pont | Process of polymerizing vinyl derivatives |
| GB329825A (en) | 1929-05-14 | 1930-05-29 | Edward Victor Hammond | Improvements in jockey pulley apparatus |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| EP0768377A1 (de) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| AU662148B2 (en) | 1991-04-10 | 1995-08-24 | Scripps Research Institute, The | Heterodimeric receptor libraries using phagemids |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
| PT744958E (pt) | 1994-01-31 | 2003-11-28 | Univ Boston | Bancos de anticorpos policlonais |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US7005504B2 (en) * | 1998-01-22 | 2006-02-28 | Genentech, Inc. | Antibody fragment-peg conjugates |
| US6362254B2 (en) | 1998-03-12 | 2002-03-26 | Shearwater Corporation | Poly(ethylene glycol) derivatives with proximal reactive groups |
| US6824766B2 (en) * | 1998-04-17 | 2004-11-30 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
| US6251382B1 (en) | 1998-04-17 | 2001-06-26 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
| DE10048417A1 (de) * | 2000-09-29 | 2002-04-11 | Roche Diagnostics Gmbh | Verbindungen mit verzweigtem Linker |
| JP4602577B2 (ja) * | 2001-03-15 | 2010-12-22 | 積水メディカル株式会社 | 前糖尿病状態のスクリーニング方法及びスクリーニング用試薬 |
| GB0124317D0 (en) * | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
| WO2003049684A2 (en) * | 2001-12-07 | 2003-06-19 | Centocor, Inc. | Pseudo-antibody constructs |
| WO2003076490A1 (en) * | 2002-03-13 | 2003-09-18 | Beijing Jiankai Technology Co., Ltd. | Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound |
| JP4490290B2 (ja) * | 2002-12-31 | 2010-06-23 | ネクター セラピューティクス アラバマ，コーポレイション | 加水分解安定性マレイミド末端ポリマー |
| KR100512483B1 (ko) | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0319588D0 (en) | 2003-08-20 | 2003-09-24 | Celltech R&D Ltd | Biological products |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| HUE026278T2 (en) | 2003-07-01 | 2016-05-30 | Ucb Biopharma Sprl | Modified Fab antibody fragments |
| DE10329948B4 (de) | 2003-07-03 | 2005-05-25 | Koenig & Bauer Ag | Heftapparat mit einem wenigstens zwei Heftköpfe tragenden Heftzylinder |
| AU2003903500A0 (en) | 2003-07-08 | 2003-07-24 | Robinson, Samantha Renae | Display device for greeting cards |
| GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
-
2003
- 2003-12-23 GB GBGB0329825.4A patent/GB0329825D0/en not_active Ceased
-
2004
- 2004-12-14 JP JP2006546297A patent/JP4833857B2/ja not_active Expired - Fee Related
- 2004-12-14 US US10/583,642 patent/US7736635B2/en not_active Expired - Fee Related
- 2004-12-14 AT AT04806061T patent/ATE533514T1/de active
- 2004-12-14 WO PCT/GB2004/005246 patent/WO2005061005A2/en not_active Ceased
- 2004-12-14 EP EP04806061A patent/EP1699491B1/de not_active Expired - Lifetime
- 2004-12-14 CA CA002545805A patent/CA2545805A1/en not_active Abandoned
- 2004-12-14 ES ES04806061T patent/ES2374201T3/es not_active Expired - Lifetime
- 2004-12-14 AU AU2004305291A patent/AU2004305291B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US7736635B2 (en) | 2010-06-15 |
| EP1699491B1 (de) | 2011-11-16 |
| WO2005061005A2 (en) | 2005-07-07 |
| AU2004305291A1 (en) | 2005-07-07 |
| GB0329825D0 (en) | 2004-01-28 |
| JP2007515463A (ja) | 2007-06-14 |
| ES2374201T3 (es) | 2012-02-14 |
| WO2005061005A3 (en) | 2005-11-03 |
| US20070128150A1 (en) | 2007-06-07 |
| AU2004305291B2 (en) | 2010-06-24 |
| CA2545805A1 (en) | 2005-07-07 |
| JP4833857B2 (ja) | 2011-12-07 |
| EP1699491A2 (de) | 2006-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0329825D0 (en) | Biological products | |
| WO2021243122A3 (en) | Engineered coronavirus spike (s) protein and methods of use thereof | |
| NO20052089L (no) | Polymerkonjugater med redusert antigenisitet, fremgangsmater for fremstillling og anvendelse derav | |
| CY1108685T1 (el) | Συστημα απελευθερωσης φαρμακου που πηζει in-situ | |
| NO20072997L (no) | Posisjonsstyrt omdanning av FVIII | |
| CY1118120T1 (el) | Συνθεσεις βασιζομενες σε πεδιο ινωδονεκτινης τυπου iii, μεθοδοι και χρησεις αυτων | |
| EA202191651A1 (ru) | Бициклические пептидные лиганды, специфичные к mt1-mmp | |
| DK1459065T3 (da) | Fremgangsmåde til målingen af styrken af glatirameracetat | |
| MX382756B (es) | Polimeros de tiol-eno degradables y metodos para hacer los mismos. | |
| BRPI0607988A2 (pt) | composto, composição farmacêutica, e método para induzir apoptose em uma célula | |
| BR0317296A (pt) | Método de tratamento de uma formação subterrânea | |
| DK1660528T3 (da) | Mutein af tåre-lipocalin | |
| ATE485331T1 (de) | Thiolselektive wasserlösliche polymerderivate | |
| CY1113684T1 (el) | Anti-mikρobiaka πεπτιδια που περιλαμβανουν μια αργινινη (arginine)- kai/ή λυσινη (lysine)- που περιεχουν υποκινητη | |
| WO2004099231A3 (en) | Glycopegylation methods and proteins/peptides produced by the methods | |
| DK1144607T3 (da) | Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger | |
| GT200800154A (es) | N-sulfonilacion selectiva de alcoholes 2-amino trifluoroalquilo sustituidos | |
| AR067627A1 (es) | Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion | |
| ATE306498T1 (de) | Von zellen präsentierte peptide | |
| DE602004016532D1 (de) | Verbindungen und kits zur herstellung von bildgebenden mitteln und bildgebungsverfahren | |
| MA27880A1 (fr) | Derives de tetrahydrocarbazole et leur utilisation pharmaceutique | |
| ATE498022T1 (de) | Universelle vervielfältigung von fragmentierter rns | |
| ATE461960T1 (de) | Verfahren zur herstellung von polymermaleimiden | |
| DE602004021501D1 (de) | Gegenüber ionisierender strahlung stabile polyarylestercarbonatzusammensetzungen | |
| YU90301A (sh) | Konjugati i postupci za njihovu proizvodnju i njihova upotreba za transport molekula kroz biološke membrane |